Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — Investor Presentation (January 2011)
13 slides from Jazz Pharmaceuticals's investor presentation, Jan 19, 2011
Slide 1: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' financial performance and growth potential, including expectations with respect to 2010 financial results, sales and earnings growth, and marke
Slide 2: Jazz Pharmaceuticals Today
Jazz Pharmaceuticals Today • Growing, profitable pharmaceutical company with high operating leverage – Two products with sales of $164M -$168M in 2010 and gross margin > 90% 1,2 – $56M - $58M in 2010 adjusted net income; $27M - $29M in 2010 GAAP net income 1,2 • Highly leverageable commercial organi
Slide 3: Xyrem - Strong Sales Growth
Xyrem - Strong Sales Growth 4Q10G 3Q10 2Q10 1Q10 4Q09 Total 2010 Xyrem Sales $140M - $142M YOY Sales Growth 45% - 47% $0 $10 $20 $30 $40 $50 $60 $32 $29 $34 $37 $40 - $42 1. Based on guidance for 2010 provided on November 4, 2010. Jazz Pharmaceuticals is not updating the amounts in that prior guidan
Slide 4: Luvox CR – Continued Sales Growth
Luvox CR – Continued Sales Growth Total 2010 Luvox CR Sales $24M - $26M YOY Sales Growth 31%- 42% 4Q10G 3Q10 2Q10 1Q10 4Q09 $5.7 $5.5 $5.8 $6.6 $6 - $8 $0 $1 $4 $6 $7 $8 $5 $3 $2 $9 1. Based on guidance for 2010 provided on November 4, 2010. Jazz Pharmaceuticals is not updating the amounts in that p
Slide 5: Strong Earnings Growth
Strong Earnings Growth 2010 GAAP EPS of $0.70 - $0.75 Based on guidance for 2010 previously provided on November 4, 2010 and estimated shares outstanding of 42 million for 4Q10. Jazz Pharmaceuticals is not updating the amounts in that prior guidance; however, Jazz Pharmaceuticals currently expects t
Slide 6: QO vexrarracestas
QO vexrarracestas
Slide 7: Slide 7
Slide 8: QO vexrarracestas
QO vexrarracestas
Slide 9: 2010 Financial Guidance
2010 Financial Guidance 1 Total Product Sales $164 – 168M Xyrem $140 – 142M Luvox CR $24 – 26M Gross Margin > 90% SG&A $69 – 71M R&D $27 – 28M GAAP EPS $0.70 – 0.75 Adjusted EPS $1.45 – 1.50 1. Based on guidance for 2010 provided on November 4, 2010. Jazz Pharmaceuticals is not updating the amounts
Slide 10: QO vexrarracestas
QO vexrarracestas
Slide 11: Slide 11
Slide 12: Jazz Pharmaceuticals
Jazz Pharmaceuticals
Slide 13: Reconciliation of Quarterly GAAP to Adjusted Financial Results and Guidance
Reconciliation of Quarterly GAAP to Adjusted Financial Results and Guidance 4Q09 1Q10 2Q10 3Q10 4Q10G 1 In millions, except per share amounts GAAP net income $5.7 $1.5 $(6.4) $13.2 $19-21 Add: Intangible asset amortization 2.1 2.1 2.0 1.9 Stock-based compensation expense 2.4 1.8 2.0 2.2 Non-cash int
Jazz Pharmaceuticals — Investor Presentation (January 2011) on 6ix